The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients

Link to article at PubMed

Open Med (Wars). 2022 Jan 24;17(1):216-220. doi: 10.1515/med-2021-0374. eCollection 2022.


Accumulated evidence suggest that the adverse outcome of severe coronavirus disease 2019 (COVID-19) is closely related to prothrombotic microvascular pathology with a high risk of venous thromboembolism. Furthermore, the first observational studies indicated that adjunct therapy with low-molecular weight heparin (LMWH) was associated with lower mortality in this cohort of patients. However, the timing of starting LMWH and the dose remain controversial in COVID-19 patients. Considering the above, the aim of this study was to reveal the rationale for using LMWH in the therapy of symptomatic COVID-19 patients based on experimental and clinical studies on LMWH in inflammatory settings with special consideration given to randomized trials.

PMID:35178474 | PMC:PMC8812716 | DOI:10.1515/med-2021-0374

Leave a Reply

Your email address will not be published.